Navigation Links
Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation
Date:2/23/2011

In addition, the CF Foundation is expanding its medical research program by $100 million over the next five years to focus on developing therapies, known as CFTR modulators, which address the underlying defect.

Vertex's VX-770 Phase 3 program involves three different clinical trials, including the trial for people age 12 and up with the G551D mutation described above. In addition, a VX-770 trial of children ages 6 to 11 with the G551D mutation is ongoing and results are expected in mid-2011. The company also announced results for a trial evaluating VX-770 in patients with two copies of the Delta F508 mutation. Safety was the study's primary focus, and adverse events were similar between the VX-770 and placebo groups in the study. Patients did not show a clinically meaningful improvement in lung function, although sweat chloride improved by a small amount.

Results from all three studies will be part of the drug application Vertex will submit to the FDA.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013 /PRNewswire/ ... period for commercially-insured patients with Type 2 diabetes, ... shown to improve health outcomes and can lead ... studies presented at the International Society for Pharmacoeconomics ... The two studies, sponsored by Valeritas, ...
(Date:5/22/2013)... -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... at the following conferences. , Deutsche Bank 38th ... 29, 2013 , Presentation time: 12:00 p.m. P.T. ... Presentation date: Wednesday June 5, 2013 , Presentation time: ... live webcast and 30-day archive of these presentations will be ...
(Date:5/22/2013)... May 22, 2013  Grifols, a global healthcare company ... results from a study demonstrating that a higher dose ... increased levels of the alpha 1 protein in ... that are considered within the normal range for healthy ... which low levels of the alpha 1 proteinase ...
Breaking Medicine Technology:Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... search for a Chief Executive Officer.  Paul Hamelin, Savient,s ... officer, will continue to lead the day-to-day operations of ... About Savient Pharmaceuticals, Inc. Savient ...
... 2010 LuxteL llc , a quality manufacturer of ... the recent sale of their only remaining manufacturing competitor, ... Ceramic Lighting business. Since April 2001, ... compatible with medical lighting produced by Olympus, Storz, Stryker, Wolf, ...
Cached Medicine Technology:Savient Pharmaceuticals Announces Search for CEO 2LuxteL Brand Is the Longest Standing Recognized Name in the Industry 2
(Date:5/22/2013)... Results from a large observational study reported ... is superior to heparin in the absence ... in patients with non-ST segment elevation acute ... (PCI)., European and US NSTE-ACS guidelines currently ... unfractionated heparin plus GP IIb/IIIa receptor inhibitors ...
(Date:5/22/2013)... NY (PRWEB) May 22, 2013 ... an exclusive partnership with Aurora Financial Systems, Inc. ... tool to companies that offer Medicare Advantage Health ... members for completing 3 out of 12 preferred ... product launched March 2013, and provides an incentive ...
(Date:5/22/2013)... MA (PRWEB) May 22, 2013 In ... hit the country’s fields and courts with donated ... Sports, a Massachusetts-based nonprofit dedicated to partnering with manufacturers ... is celebrating the donation of $8.8 million in sports ... more than a half-million kids outfitted for physical activity. ...
(Date:5/22/2013)... York City, New York (PRWEB) May 22, 2013 ... American: Causes, Culture, Consequences, and Cost ” article published recently ... obesity is fully justified. The Centers for Disease Control ... U.S. adults aged 20 and over are overweight, 35.7% are ... facts are highlighted in this investigative article. In particular, the ...
(Date:5/22/2013)... 2013 Following the success of last ... Fit Body Boot Camp Kincardine has announced it ... Challenge starting on June 3rd at its Kincardine ... Street, Kincardine, Ontario.     , Fit Body Boot Camp’s 1,000 ... local community residents to lose a total of 1,000 ...
Breaking Medicine News(10 mins):Health News:Registry questions superiority of bivalirudin over heparin 2Health News:Integrated Printing Solutions and Aurora Financial Systems, Inc. Create Partnership for Healthcare Incentive Card 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 2Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 3Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3
... ... inflammatory bowel disease (IBD) research were awarded the Crohn,s & Colitis Foundation,s prestigious ... & Research Conference ( http://www.advancesinibd.com/ ) in Hollywood, Florida on December 4th. ... New ...
... , , ... a new market research report is available in ... strategic assessment of the competitive environment is widely ... responsibilities, the task crucial to business survival, growth ...
... 17 Good Samaritan Hospital is changing the way women manage ... Good Samaritan Hospital Women,s Center For Bladder & Pelvic Health. , ... - lack of bladder control (urinary incontinence) and slippage of the ... women report some degree of urinary leakage and one out of ...
... 2009 Canadian teenagers are among the largest consumers ... drug on young brains are worse than originally thought, ... psychiatric researcher from the Research Institute of the McGill ... Neurobiology of Disease , suggests that daily consumption of ...
... particle might someday ease accompanying lung infections , THURSDAY, Dec. ... infected with the swine flu virus, and researchers say they,ve ... the severity of the illness appears to be a molecule ... off germs and disease. Researchers who analyzed levels of the ...
... ... examinations underscore the important role that competent, educated CT technologists play in minimizing ... , ... NM (Vocus) December 16, 2009 -- Two recent studies examining radiation doses delivered ...
Cached Medicine News:Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 2Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 3Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 4Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 5Health News:Reportlinker Adds Top Ten World's Leading Life Science Intermediates Companies 2Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 2Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 3Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 2Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 3Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 4
... The Summit SI Spinal Fixation ... for rigid posterior fixation of ... spine. The simplicity and versatility ... optimize the construct based on ...
OctaFix is designed specifically to provide stability and fixation where it is most needed....
...
...
Medicine Products: